Andreas Gollner
@andreas_gollner
Followers
319
Following
1K
Statuses
225
Medicinal Chemist - SLCs - Targeted Protein Degradation - PPI inhibitors - Open Innovation enthusiast
Wien, Österreich
Joined May 2017
First disclosure of the MDM2 inhibitor BI 907828. @norbertkraut1 @D_B_McConnell. Thank you for presenting and working ob this exciting project together @ChemHaWei
1
7
38
RT @schoffski: Clinically relevant anti-tumor activity of the MDM2 antagonist brigimadlin in advanced dediff. liposarcoma in first line in…
0
8
0
RT @schoffski: Superior activity of MDM2 antagonist brigimadlin in „locally advanced“ and „prior surgery“ subsets of patients with dediffer…
0
9
0
RT @giuliosf: Do you want to know with which proteins an SLC membrane transporter socializes? Our @RESOLUTE_IMI series of 4 manuscripts con…
0
29
0
Nice feature article in @cenmag on our recent pan-KRAS degrader article.
The enzyme KRas has become a popular cancer target for drugmakers in the last decade. Now, scientists are reporting a compound that could lead to new therapeutics: .
0
0
7
The first of a series of four papers transforming SLC research. Congratulations to the RESOLUTE consortium!
We are excited to kick off our series of 4 manuscripts from the RESOLUTE consortium by sharing the metabolic mapping of the Solute Carrier Superfamily (!
0
0
4
RT @Boehringer: Our collaborative research with @UoDCeTPD on a novel approach to target several KRAS mutants, a key protein involved in can…
0
14
0
Happy to share the collaborative work of @alessiociulli group and @Boehringer Vienna on pan-KRAS degraders. It was great to work together with so many talented people to deliver ACBI3. Targeting cancer with small-molecule pan-KRAS degraders | Science
5
8
48
RT @norbertkraut1: Congrats to our team @Boehringer for publishing our latest research on targeting #MDM2 in MCT @MCT_AACR @AACR Discovery…
0
5
0
RT @agwaterson: BI-0474 is a novel, covalent inhibitor of KRAS G12C, discovered by a @VanderbiltU, @Boehringer collaboration by first optim…
0
2
0
RT @gsf_lab: Are you eager to combine protein-protein interaction data of transmembrane proteins with the knowledge from protein structures…
0
8
0
I’m happy to share this new method to make substituted #indazoles which was recently published in OL @JOC_OL. It is particularly useful if your molecule doesn’t like reductive conditions. Big thank you to the team at Boehringer Ingelheim.
0
2
26
RT @DrLizConnolly: Brigimadlin: MDM2-p53 antagonist for #liposarcoma by @schoffski at #CTOS2023 Ph 1a/1b; n=145 ✅ Dose finding complete 💊…
0
16
0
Great to see applications of MDM2::p53 inhibitors beyond oncology and great to see this work published! @FilaretoAntonio @ChemHaWei
Take a look at our recent work a partnership b/w Boehringer Ingelheim (RBB) and Uni Kentucky. Inhibition of Mdm2::p53 binding reduces senescent cell to enhance musc reg and hypertrophy in old mice. A big thanks to Profs Peterson and Dungan.
0
2
7
RT @schoffski: Treatment with a potent MDM2 antagonist in p53 wildtype liposarcoma induces p53 mutations, but interestingly this does not l…
0
13
0
Exciting times to work in small-molecule drug discovery! So many new opportunities; incredible pace :
0
4
18
Very happy to share this pre-print on pan-KARS degraders! @UoDCeTPD @Boehringer collaboration. Thanks to the great team Johannes Popow, @farnaby84, Christiane Kofink, @ChemHaWei, Peter Ettmayer, @alessiociulli and many more colleagues
0
9
36
RT @Solgatetx: A fantastic conference in a stunning venue to celebrate a field-changing effort by the @RESOLUTE_IMI consortium! We are than…
0
2
0